Cerdulatinib (PRT062070): A dual SYK/JAK inhibitor in patients with relapsed/refractory b-cell malignancies—Pharmacokinetic and pharmacodynamic outcomes with twice-daily (BID) vs once-daily (QD) dosing.

Paul A. Hamlin,Ian W. Flinn,Nina D. Wagner-Johnston,Jan Andreas Burger,Glenn Michelson,Anjali Pandey,Matt Birrell,Greg Coffey,Janet Leeds,Alice sabalvaro-Torres,Yvonne Kim,John T. Curnutte,Manish R. Patel

Cerdulatinib (PRT062070): A dual SYK/JAK inhibitor in patients with relapsed/refractory b-cell malignancies—Pharmacokinetic and pharmacodynamic outcomes with twice-daily (BID) vs once-daily (QD) dosing.

2016

Paul A. Hamlin
Ian W. Flinn
Nina D. Wagner-Johnston
Jan Andreas Burger
Glenn Michelson
Anjali Pandey
Matt Birrell
Greg Coffey
Janet Leeds
Alice sabalvaro-Torres
Yvonne Kim
John T. Curnutte
Manish R. Patel

7557Background: Subsets of B cell malignancies demonstrate a reliance on BCR and/or cytokine JAK/STAT signaling for survival. Cerdulatinib is a dual SYK/JAK inhibitor, currently in a phase I dose e...

Keywords:

Refractory
Cerdulatinib
Syk
Dosing
Pharmacodynamics
Pathology
Medicine
Pharmacology
B cell
Pharmacokinetics
Oncology
Internal medicine
Cytokine
breakpoint cluster region

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations